Pfizer to Buy Anacor in Deal Valued at $5.2 Billion

The transcript discusses Pfizer's acquisition strategy, focusing on its offer for Sanacore, a company with products for toenail fungus and eczema. Pfizer aims to expand its future business by acquiring smaller companies. The timing is strategic due to available resources after a blocked deal with Allergan. Additionally, the transcript covers Gannett's ongoing bid for Tribune, highlighting negotiation tactics and financial considerations.

How does the acquisition of Sanacore fit into Pfizer's future business plans?

What financial resources does Pfizer have that enable them to pursue acquisitions?